scholarly journals Randomised clinical trials on outpatient treatment of SARS‐COV‐2 infection: Light and shadows

2021 ◽  
Vol 75 (12) ◽  
Author(s):  
Luigi Cavanna ◽  
Chiara Citterio
Keyword(s):  
Clinical Trials ◽  
Outpatient Treatment ◽  
Randomised Clinical Trials

Anthroposophical Medicine: A systematic review of randomised clinical trials

2004 ◽  
Vol 116 (11-12) ◽  
pp. 407-408 ◽  
Author(s):  
Gunver S. Kienle ◽  
Harald J. Hamre ◽  
Helmm Kiene
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomised Clinical Trials ◽  
Anthroposophical Medicine

scholarly journals Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials

2021 ◽  
Vol 164 ◽  
pp. 105404
Author(s):  
Hao Niu ◽  
Judith Sanabria-Cabrera ◽  
Ismael Alvarez-Alvarez ◽  
Mercedes Robles-Diaz ◽  
Simona Stankevičiūtė ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Liver Injury ◽  
Meta Analysis ◽  
Randomised Clinical Trials ◽  
Drug Induced ◽  
Drug Induced Liver Injury

scholarly journals Effect of tranexamic acid in arthroscopic anterior cruciate ligament repair: A systematic review and meta-analysis of randomised clinical trials

2021 ◽  
Vol 29 (2) ◽  
pp. 230949902110173
Author(s):  
Tze Khiang Tan ◽  
Ka Ting Ng ◽  
Hui Jane Lim ◽  
Ross Radic
Keyword(s):  
Clinical Trials ◽  
Anterior Cruciate Ligament ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Cruciate Ligament ◽  
Meta Analysis ◽  
Lysholm Score ◽  
Randomised Clinical Trials ◽  
Postoperative Blood Loss ◽  
Anterior Cruciate

Purpose: Perioperative blood loss remains a major challenge to surgeons in anterior cruciate ligament reconstruction (ACLR) surgery, despite of the introduction of minimally invasive approach. Tranexamic acid (TXA) is believed to reduce blood loss, which may minimise the complication of postoperative haemarthrosis with insufficient evidence on its effectiveness in ACLR. The primary aim of this study was to examine the effect of TXA on postoperative blood loss and other secondary outcomes in patients undergoing arthroscopic ACLR surgery. Method: PUBMED, EMBASE, MEDLINE and CENTRAL database were systematically searched from its inception until November 2020. All randomised clinical trials (RCTs) comparing TXA (intravenous or intra-articular) versus placebo in the arthroscopic ACLR surgery were included. Case series, case report and editorials were excluded. Results: Five RCTs comprising of a total of 580 patients (291 in TXA group, 289 in control group) were included for qualitative and quantitative meta-analysis. In comparison to placebo, TXA group was significantly associated with lower postoperative blood loss (mean difference (MD): −81.93 ml; 95% CI −141.80 to −22.05) and lower incidence of needing knee aspiration (odd ratio (OR): 0.19; 95% CI 0.08 to 0.44). Patients who randomised to TXA were also reported to have better range of movement (MD: 2.86; 95% CI 0.54 to 5.18), lower VAS Pain Score (MD: −1.39; 95% CI −2.54 to −0.25) and higher Lysholm Score (MD: 7.38; 95% CI 2.75 to 12.01). Conclusion: In this meta-analysis, TXA reduced postoperative blood loss with lesser incidence of needing knee aspiration along with better range of knee movement and Lysholm score in patients undergoing arthroscopic ACLR surgery.

Sign in / Sign up

Export Citation Format

Share Document